Brief: 3D Medicines Posts FY Loss Attributable Of RMB1.02 Bln
30/03/2023 16:29
March 30 (Reuters) - 3D Medicines Inc 1244.HK :
* FY LOSS ATTRIBUTABLE RMB1.02 BILLION VERSUS LOSS RMB1.43
BILLION
* FY REVENUE RMB567.4 MILLION VERSUS RMB60.3 MILLION
Source text for Eikon: ID:nHKS8T4hlv
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology